Adverse Reactions to First-Line Anti-Tuberculosis Drugs As a Risk Factor of Pulmonary Tuberculosis Treatment

Abstract

First-line drugs for tuberculosis (TB) still need to be used to treat pulmonary TB. Bad drug reactions (ADRs), on the other hand, make it hard to stay on treatment, which can lead to less-than-ideal results and the spread of TB that drugs can't stop. ADRs can happen with first-line drugs used to treat TB. This review talks about these issues and how they make it tough for people to keep up with their treatment. It also gives ideas for how to make these issues less important.

Keywords

Introduction

About two million people around the world get sick every year from Mycobacterium tuberculosis. First-line treatments like Ethambutol (EMB), isoniazid (INH), pyrazinamide (PZA), and isoniazid are often used to treat tuberculosis (3TB). These drugs are very good at getting rid of the infection, but they can also make it hard to stay on treatment, which is bad for the therapy as a whole.  MDR-TB is more likely to happen to people who don't follow their treatment plans. Even worse, the drugs they are taking often make this worse. Some of them can hurt your brain and liver a lot, so you may need to change or stop taking them. Some of these reactions are already bad, but some of them make stomach problems even worse. To help people get better and stop drug resistance, it's important to know about the different types of ADRs and keep an eye on things.
Which side effects do first-line drugs for TB cause the most often? In what ways does this make it harder for people to keep up with their care? What can be done to help the patients' health and health care with these side effects?

Impact of ADRs on Treatment Outcomes

People who get sick from drugs are less likely to stay in care. It's more likely that treatment won't work, people will use drugs again, and therapy will fail. ADRs make people more likely to stop their treatment, which keeps M. tuberculosis alive and helps MDR-TB spread.

Strategies to Mitigate ADRs

Discovery and tracking early: ADRs can be found early with the help of ongoing tracking in biochemistry and medicine.
1. Giving the Patient Information: Teaching patients about possible bad drug responses (ADRs) and how to handle them can help them follow their treatment plan.
2. Programs for pharmacovigilance: Making it easy to report bad drug reactions (ADRs) can help treatment plans work well.
3. Personalized medicine—Genetic testing to find out if a person is more likely to have ADRs could help make treatment plans safer.

REVIEW OF LITERATURE         

1. Damage to the liver and how it changes how TB is treated
Sharma et al. (2020) studied people with tuberculosis who were starting their first drug-based treatment for TB to learn more about how drugs can harm the liver (DILI). About 10% to 15% of the people who were checked had problems with their liver. What they were doing and how they were doing it had to be changed. They stressed how important it is to check liver function often so things don't get worse.
2. Damage to the nerves in the limb having to do with isoniazid
Singh and Verma's 2019 study looked at how common peripheral neuropathy is in people with TB who take isoniazid. Neuropathy was more likely to happen to people who didn't eat enough or who had diabetes. One study found that getting more pyridoxine (vitamin B6) can help people with nerve problems feel less pain and be more likely to stick with their treatment.
3. If you take Rifampicin and Pyrazinamide together, you might get acid reflux.
Kumar et al. (2021) did a study on how frequent stomach problems like nausea, vomiting, and abdominal pain were in TB patients who were taking rifampicin and pyrazinamide-based medicines. One-third of the patients had mild to moderate stomach pain that got better with extra care, like giving them medicine with food or medicine to make them feel better when they were sick.
4. It could make your eyes hurt
Patel and Rao looked into how Ethambutol changed the health of people with tuberculosis this year. About 5% of the people who took part in the study had trouble telling the difference between red and green. They wrote that people who are losing a lot of vision should stop taking Ethambutol and get regular eye exams to find problems early.
5. Sore skin and other signs of being too gentle
Ghosh et al. (2020) said that the drugs made people with TB who were getting first-line treatment sick and gave those fevers and spots on their skin. From earlier studies, they knew that most people did well after getting medical help and trying drugs again. When things went badly, though, they needed cortisone shots and new drug plans.
6. Rifampicin can make your kidneys hurt.
About 2% of the time when rifampicin was used to treat nephrotoxicity, Chakraborty et al. (2022) found that the immune system caused immediate kidney damage. A lot of people talked about how important it is to check on someone's kidney health and change their medicine or dose if they already have kidney troubles.
What changes about the risks of getting MDR-TB and seeing a TB doctor because of ADRs?
The 2019 study by Gupta et al. looked into how multi-drug-resistant tuberculosis (MDR-TB) grows and why some people stop taking their drugs as often as they should. Major ADRs caused more people to stop treatment, which made it harder to kill germs and stop the spread of MDR-TB. In order to lower these risks, they believed that early finding ways, teaching patients, and starting pharmacovigilance programs would be useful.
How often do first-line TB drugs not work?
We don't know how often ADRs with FLDs happen around the world. The number of ADRs varies from 8 to 85% around the world.3, 7–13 Docs may use different terms for ADRs, which could cause the numbers to be different. Most of the time, the ADRs were either reported by the patient (subjective) or found by the doctor (objective) based on medical evidence. To keep track of them, they were put through a lot of tests in the lab. All or most of the ADRs were looked at. Some people with HIV, diabetes, and other health problems changed how they took some TB drugs and how much they took. Some other types of drugs that these drugs can mix with are oral diabetes medicines, ART medicines, and medicines used to treat ADRs. People in Nigeria who were getting short-course and directly observed treatment (DOTS) were looked at in a study. Between 6 and 8 months, 14% to 13% of ADRs happened.10 The Brazilian National Ministry of Health said that 5 to 20% of people who were given the old FLDs had weak to moderate bad reactions to them. Only about 2% of the time, but in expert clinics it could happen up to 8% of the time, important or dangerous bad responses to drugs happened. It had to be changed or stopped because of these ADRs.

Epidemiology of ADRs Treated with Second-Line Anti-TB Drugs

People used to think it would be hard to treat people with MDR-TB because the SLDs are so dangerous and the treatment takes 24 to 27 months. The research showed that ADRs were present in 69 to 96% of cases around the world.19–23 ADRs and FLDs happen at different rates because of mostly the same things. DR-TB patients use both old and new drugs. Linezolid (Lzd) is an old drug. Bedaquiline (Bdq) and delamanid (Dlm) are new drugs. GI (12–70%) and ototoxicity (0.5–100%) were the side effects (ADRs) that people who took SLDs most often had. Between 5% and 45% of patients have said they have tinnitus, and between 6% and 33% have said they are deaf. Most of the time, aminoglycosides that are injected, such as kanamycin (Km), are what cause ototoxicity. This one might have been worse because of the Ofloxacin (Ofx) and Cycloserine (Cs) that were used together. These drugs can hurt the ears. We need to find out more about these results to be sure they are possible. 19–60% of people with MDR-TB have stopped treatment because of major adverse drug reactions (ADRs) caused by SLDs.19–23 The high rate was thought to be because public health programs caught the disease early and kept it under tight control. Iranians who used injectable Km and Cs were told they could go blind or get headaches and insanity. Because of this, the drugs had to be stopped and/or switched out a lot.23. ADRs, like hearing loss and mental health problems, should be closely watched in people with MDR-TB while they are being treated. Not many people have talked about how often ADRs happen in India.19, 24–28

Specific Adverse Drug Reactions Associated with Anti-TB Drugs

Getting sick or throwing up  The medicines used to treat tuberculosis can make your stomach and intestines hurt. You could die if something bad happens. You might get sick and throw up. Any FLD can have this kind of GI trouble, and drugs can help. In the study by Shinde et al., the worst side effects of drugs were stomach problems like being sick, throwing up, and having pain in the stomach. They looked at 893 people. This was true 12.5% of the time.29 Also in China, GI ADRs were found in 3.74 percent of the 4,304 patients who were tracked over time in a different study. Seven of these people only needed to go to the hospital.30 It hurts the liver inside the body; it looks a lot like acute viral hepatitis. Hepatitis E drugs can also make you sick with HIV. Some TB drugs can hurt the liver. This can show up as a short-term rise in transaminases with no other signs. The liver can also stop working all of a sudden. Around the world, 2% to 39% of people will hurt their liver.31 Hepatotoxicity is more likely to happen to Indians than to Westerners.32, 33 Drugs hurt the liver all the time, but some people are more likely to get hurt than others. Poor places have had more sick people than any other. People who have had tuberculosis or jaundice in the past are more likely to get really sick as they get older. Those who have liver disease, use drugs without thinking, or have used drugs without thinking are more likely to do this.34,35 Ten to twenty percent of these patients had three times more alanine aminotransferase after being given pure H.33,36 Five percent of people with R had higher levels of bile and liver acids in their blood for a short time. There was no pain. These people had both types of the virus 2.7% of the time when they got hepatitis. 2.7% of those who got it took R with H, but only 1.1% of those who took R with drugs other than H for TB did.33  Your mind is not working right  People who have Hepatitis H. could lose their minds, have seizures, forget things, or even die.44 some mental illnesses don't seem to have anything to do with H. H, on the other hand, can mess up many cellular processes that neurons need to work right. B6 is hard to get enough of because too much H gets rid of it. It's not broken down this way by itself. A lot of the people who have been talked about have shown that H has made them crazy. Jackson wrote in 1957 about five people who went crazy because of H. The big ideas and dreams of these people were hard to grasp. They were happy and sad at the same time. A lot of fights happened. That none of these people had ever been crazy before.45  Eye pain and headaches for treating TB; E is a very important FLD. Most likely, E. is to blame for the pain in your back. It can be fixed most of the time. But sometimes it can't be fixed, and the person will always be blind. This depends on how long the drug stays in your body and how strong it is.47 RBN will happen to 18% of people who take more than 35 mg/kg/day of E for more than two months. Five to six percent of people who take 25 mg/kg/day will get sick. Hearing loss
Most of the damage that streptomycin (S) does is to the vestibular system. Km and Cm, on the other hand, don't hurt hearing aids as much. Hearing tests have shown that up to 25% of people who are exposed to S may have ototoxicity.51 The Indian study was very important because it looked at how short-term treatment could help people with lung TB. A lot of people took part in the study. 16.1% of the time, people who were given S got dizzy, and 5% of the time it was really bad.52 among these people, 10% had to stop taking the drug. The amount had to be raised about 20% of the time. 10.12% of people who took the drug in the first 3.8 ± 2.6 months had ototoxicity. There was no difference between the two in this case.53 Indian people with DR-TB who were taking drugs had a high rate of ototoxicity (27.01%) when pure tone testing was used to check on them every so often. Making noise Drugs can make your blood and immune system weaker because different people take different amounts at different times. Red blood cell purpura and hemolytic anemia have been linked to it. A study in Brazil looked at people and found that 0.1% of them had low platelets, white blood cells, eosinophil’s, hemolytic anemia, agranulocytosis, vacuities, acute interstitial nephritis, and other conditions.33,54 A few studies found that people in Asia were allergic to FLDs 2.02% to 2.35 % of the time and had hemoematological ADRs 0.10 to 0.7% of the time. Platelet count drops quickly in people who are hurt a lot. Thrombocytopenia is the name for this. The author learnt these things about what could go wrong with the blood while it was being treated. Most of the time, R. aeruginosa is to blame for TB drugs that lower platelet numbers.54,55 Not many people have said that getting Z, H, or E made them lose a lot of platelets. People think that a problem with the safety system is to blame for these. A low platelet count isn't always linked to an S number between 54 and 57. Bad drug responses (ADRs) in the blood have been linked to LZD. Your platelet count is likely to be low; in fact, it can happen up to 11.8% of the time.58 ADRs like low platelet count and myelosuppression don't happen as often as thrombocytopenia. These adverse drug reactions (ADRs) happen in the blood and depend on how much of the drug was taken. Help them get better by seeing the right doctor.  How to Deal with Bad Drug Reactions People who are taking TB drugs need to deal with the adverse drug reactions (ADRs) that can happen so that they can stay on their treatment plans. This is especially important for people with DR-TB who take SLDs. Drug Control Programs all over the world have agreed to follow rules that keep people safe. This is what the WHO says about pharmacovigilance: "the science and activities related to the detection, assessment, understanding, and prevention of ADRs or any other drug-related problem."72 We need to look at both the good and bad things about the drug in order to help people more. As part of the National Programs, ADRs should be checked in a certain way every so often. To do this, you should tell your doctor about your symptoms and get lab tests at the start and whenever they think it's necessary. Lab tests should quickly find bad drug responses (ADRs) that are hard to find so that big effects aren't missed. Drug interactions are more likely to happen in older people, people who drink too much, drug addicts, people who are malnourished, people with chronic kidney disease or liver disease, people who have a history of allergies or adverse drug reactions (ADRs), people who are taking other medications, or people who are on ART or medications for treating opportunistic infections. These people should be watched by more and more people.

HOW TO HELP PEOPLE WHO HAVE BEEN IN A DRUG ACCIDENT AND HAVE HIV OR TB
People with HIV are more likely to have adverse drug reactions (ADRs) when they take drugs to treat TB or other illnesses. Anytime, these ADRs might happen. The more disability there is, the higher the chance of ADRs happening.20, 21, 26 there are many drugs that could cause the ADRs when someone is taking medicine for both DR-TB and HIV at the same time. People in this group shouldn't stop taking all of their drugs and then slowly start taking them again, because it's possible that they will build up immunity to them, especially to ART. Remember that not a lot of information is available about how often ADRs happen. People still take most drugs even though they know that ADRs could happen because the benefit is greater than the risk. It might not be a good idea to stop someone from taking two drugs that work together. They should instead keep a close eye out for adverse drug reactions (ADRs). It doesn't matter if the doctor works for the government or a private company; they have to report every case to the right DOTS station so that the patient can get more care.

HISTORY OF DRUG USES
Isoniazid (INH) is made up of the chemicals C?H?N?O.
For Isoniazid (INH): How Drugs Are made the ring is made up of six sulphur atoms and one nitrogen atom. At the fourth spot, a hydrazine (-CONHNH?) group joined the pyridine ring. It is important to keep in mind that isoniazid the cell wall of Mycobacterium tuberculosis needs these acids to work right. Bugs will die if they can't make them. Why does INH play such a big role in treating TB? Since it kills germs. You should take 5 mg/kg every day, but you can take up to 300 mg all at once. Even though INH does its job, it has been linked to a number of bad drug responses (ADRs). It hurts the stomach the most. Being red, sick, or even quickly losing your liver can be signs of a really bad case. Some people don't get enough vitamin B6 pyridoxine because of INH. Also, these people have peripheral neuropathy, which makes their limbs tingle, burn, and go numb. Some other ADRs that have been seen are brain damage, skin spots, and stomach problems like feeling sick and throwing up. People who already have liver disease or are allergic to INH shouldn't be given it because of these risks. Making sure you get regular liver function tests (LFTs) is important to find early signs of hepatotoxicity. A study of the brain helps figure out new ways nerve pain can show up. If 10–50 mg of INH is taken every day with pyridoxine, nerve damage is less likely to happen. Find and treat ADRs early on to make people more likely to stay in treatment and less likely to quit or become resistant to drugs.

CONCLUSION

It is hard to treat TB because first-line drugs have side effects that make it harder to do so. Some of the most important ways to improve adherence and lower the chance of drug-resistant TB are early detection, patient education, and pharmacovigilance. The goal is to create personalized treatment plans that keep therapy working well while lowering the risk of bad drug effects. During TB treatment, a number of ADRs can happen. DS-TB and DR-TB treatments have a lot of adverse drug reactions (ADRs), some of which are very bad. This is especially true during the intensive part of treatment. Some ADRs happen more often in people with HIV and DR-TB. Most ADRs can be safely treated in a community-based treatment program, even in places with few resources, so the person doesn't have to stay in the hospital. Very bad ADRs should be a worry when treating DR-TB patients, but they shouldn't stop the urgent need to quickly scale up SLDs. ADRs can be found in places with few resources by using clinical proof.

REFERENCES

1. World Health Organization, Requirements for Adverse Reaction Reporting. Geneva, Switzerland: World Health Organization; 1975
2. Forget EJ, Menzies D. Adverse reactions to first-line antituber-culosis drugs. Expert Opin Drug Saf 2006;5(2):231–249
3. Gülbay BE, Gürkan Ö, Yildiz Ö, et al. Side effects due to pri-mary antituberculosis drugs during the initial phase of ther-apy in 1149 hospitalized patients for tuberculosis. J Respir Med 2006;100:1834–1842
4. Tan WC, Ong CK, Kang SC, Razak MA. Two years review of cuta-neous adverse drug reaction from first line anti-tuberculous drugs. Med J Malaysia 2007;62(2):143–146
5. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356(9237):1255–1259
6. Singh A, Prasad R, Balasubramanian V, Gupta N, Gupta P. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clin Epidemiol Glob Health 2015;3:s80–s90
7. Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007;11(8):868–875
8. Butov D, Kuzhko M, Stepanenko G, Butova T. Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse (RTB) and newly diagnosed tuberculo-sis (NDTB) European Respiratory Journal 2018;52(s62:PA2700
9. Dosumu EA. Side-effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuber-culosis subjects in Nigerians: a controlled clinical study. Niger Postgrad Med J 2002;9(1):34–37
10. Arbex MA, Varella MdeC, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol 2010;36(5):626–640
11. Vieira DE, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J Bras Pneumol 2008;34(12):1049–1055
12. Breen RA, Miller RF, Gorsuch T, et al. Adverse events and treat-ment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006;61(9):791–794
13. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev 2001(4)::CD000970
14. Mehrotra ML. Agra study of short course chemotherapy in pul-monary tuberculous patients. Indian J Tuberc 1982;29:29–39
15. Dedun AR, Borisagar GB, Solanki RN. Impact of adverse drug reaction of first line anti - tuberculous drugs on treatment outcome of tuberculosis under revised national tuberculo-sis control programme. International Journal of Advances in Medicine 2017;4:645–649
16. Naser SM, Nandy M, Banu P, et al. Adverse drug reaction monitoring through active surveillance of antitubercular therapy in an urban tertiary care center. Community Acquir Infect 2016;3:51–54
17. Mandal PK, Mandal A, Bhattacharyya SK. Comparing the daily versus the intermittent regimens of the anti-tubercular che-motherapy in the initial intensive phase in non-HIV, spu-tum positive, pulmonary tuberculosis patients. J Clin Diagn Res 2013;7(2):292–295
18. Prasad R, Singh A, Gupta N, Giridhar BH. Epidemiology of adverse drug reaction with second line drugs among patients treated for multi- drug resistant tuberculosis.
19. European Journal of Biomedical and Pharmaceutical Sciences 2015;2:553–561
20. Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother 2017;72(7):1871–1879
21. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of MDR-TB: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2005;9:1027–1033
22. Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrug-resistant tuberculosis treatment with a standard-ized regimen: a report from Iran. Am J Ther 2011;18:e29–e34
23. Singla R, Sarin R, Khalid UK, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis 2009;13(8):976–981
24. Joseph P, Desai VB, Mohan NS, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011;133:529–534
25. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretro-viral and second line anti-TB treatment in Mumbai, India. PLoS One 2012;7(7):e40781
26. Dela AI, Tank NKD, Singh AP, Piparva KG. Adverse drug reac-tions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study. Lung India 2017;34(6):522–526
27. Prasad R, Singh A, Srivastava R, et al. Adverse drug reaction in the treatment of multi drug resistant tuberculosis. Indian Tuberc 2013;144(4, suppl) :390A
28. Shinde KM, Pore SM, Bapat TR. Adverse reactions to first-line anti-tuberculous agents in hospitalised patients: pat-tern, causality, severity and risk factors. Indian J Med Spec 2013;4:1–4
29. Lv X, Tang S, Xia Y, et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One 2013;8(6):e65037
30. Anand AC, Seth AK, Paul M, Puri P. Risk factors of hepatotox-icity during anti-tuberculosis treatment. Med J Armed Forces India 2006;62(1):45–49
31. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic tox-icity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986;67(2):99–108
32. Blumberg HM, Burman WJ, Chaisson RE, et al; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am Respir Crit Care Med 2003;167(4):603–662
33. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99(2):465–471
34. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51(2):132–136
35. Baghaei P, Tabarsi P, Chitsaz E, et al. Incidence, clinical and epi-demiological risk factors, and outcome of drug-induced hepa-titis due to antituberculous agents in new tuberculosis cases. Am J Ther 2010;17(1):17–22
36. Prasad R, Verma SK, Chowdhury SR, Chandra M. Predisposing factors in hepatitis induced by anti-tuberculosis regimens containing isoniazid, rifampicin and pyrazinamide: a case con-trol study. JIMI 2006;9:73–78
37. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hep-atotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience.
38. from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002;6(11):995–1000
39. Kumar R, Bhatia V, Khanal S, et al; Shalimar. Antituberculosis therapy-induced acute liver failure: mag-nitude, profile, prognosis, and predictors of outcome. Hepatology 2010;51(5):1665–1674
40. British Thoracic Association. A comparison of the toxic-ity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association. Tubercle 1968;49(2):125–135
41. DR-TB STAT (Drug-Resistant TB Scale-Up Treatment Action Team). Treatment of Drug-Resistant TB with New and Re-Purposed Medications: a Field Guide. Cleveland, DR-TB STAT, 2018; 1-55. Accessed at: http://drtb-stat.org/
42. Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, Shankar PR. Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara. J Pak Med Assoc 2008;58(10):531–536
43. Philadelphia Tuberculosis Control Program. Guidelines for the Management of Adverse Drug Effects of Anti-mycobacterial Agents. Available at: https://medbox.org/ pdf/5e148832db60a2044c2d3f51. Accessed December 11, 2020
44. Prasad R, Garg R, Verma SK. Isoniazid- and ethambutol-induced psychosis. Ann Thorac Med 2008;3(4):149–151
45. Jackson SL. Psychosis due to isoniazid. BMJ 1957;2(5047):743–746
46. Kass JS, Shandera WX. Nervous system effects of antitubercu-losis therapy. CNS Drugs 2010;24(8):655–667
47. Tsai RK, Lee YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther 1997;13(5):473–477
48. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966;135(2):904–909
49. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;45(1):161–170
50. Moore RD, Smith CR, Lietman PS. Risk factors for the devel-opment of auditory toxicity in patients receiving aminoglyco-sides. J Infect Dis 1984;149(1):23–30
51. Prazi? M, Salaj B. Ototoxicity with children caused by strepto-mycin. Audiology 1975;14(2):173–176
52. Berte   SJ,   Dimase   JD,   Christianson   CS.   Isoniazid, para-aminosalicylic acid and streptomycin intolerance in 1,744 patients. An analysis of reactions to single drugs and drug groups plus data on multiple reactions, type and time of reactions, and desensitization. Am Rev Respir Dis 1964;90:598–606
53. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dos-ing regimen on rates of observed nephrotoxicity and ototoxic-ity. Antimicrob Agents Chemother 1999;43(7):1549–1555
54. Garg R, Gupta V, Mehra S, Singh R, Prasad R. Rifampicin induced thrombocytopenia. Indian J Tuberc 2007;54(2):94–96
55. Prasad R, Mukerji PK. Rifampicin induced thrombocytopenia. Indian J Tuberc 1989;36:171–175
56. Prasad R, Mukerji PK. Ethambutol-induced thrombocytopae-nia. Tubercle 1989;70(3):211–212
57. Kant  S,  Verma  SK,  Gupta  V,  Anand  SC,  Prasad  R. Pyrazinamide             induced   thrombocytopenia.     Indian J Pharmacol 2010;42(2):108–109.